| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Vopratelimab | JTX-2011 | Phase 2 Clinical | Jounce Therapeutics Inc | Carcinoma, Non-Small-Cell Lung; Neoplasms | Details |
| Feladilimab | GSK-609; GSK-3359609 | Phase 2 Clinical | Glaxosmithkline Plc | Head and Neck Neoplasms; Multiple Myeloma; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| Acazicolcept | ALPN-101 | Phase 2 Clinical | Alpine Immune Sciences Inc | Autoimmune Diseases; Graft vs Host Disease; Inflammation; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders | Details |
| MEDI-570 | Phase 1 Clinical | Japan Tobacco (Hong Kong) Ltd | Lupus Erythematosus, Systemic; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides | Details | |
| Izuralimab | XmAb-23104; XmAb-104 | Phase 1 Clinical | Xencor Inc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Endometrial Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Nasopharyngeal Carcinoma; Pancreatic Neoplasms; Sarcoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | Details |
| Anti-ICOS (Bristol Myers Squibb) | BMS-986226 | Phase 1 Clinical | Bristol-Myers Squibb Company | Neoplasms | Details |
| anti-ICOS mAb (Bristol-Myers Squibb) | Phase 1 Clinical | Bristol-Myers Squibb Company | Neoplasms; Solid tumours | Details |